Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

NCT04840485 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 548

Last updated 2024-05-22

No results posted yet for this study

Summary

The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis

Conditions

Interventions

DRUG

SHR-1314

SHR-1314 high dose

DRUG

SHR-1314

SHR-1314 low-dose

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2023-11-03
Completion
2024-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04840485 on ClinicalTrials.gov